EUVIMEDEUVIMED entdecken
Crossref

Molecular Boomerangs Against Cancer: Design, Synthesis, Biological Evaluation, and In Silico Study of Novel Dual PARP‐1/EGFR Inhibitors

Haytham O Tawfik iD, Amr Tayel iD, Salma M Hefny iD, Tarfah Al-Warhi, Nada K Sedky iD, Anwar A El-Hamaky iD, Nourhan A Khattab iD, Ahmed K B A W Farouk iD, Moataz A Shaldam iD, Wagdy M Eldehna iD, Mohamed S Nafie iD

Drug Development Research · 2026-06 · 87 (4)

DOI: 10.1002/ddr.70325 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 28.05.2026. Verfasst von Haytham O Tawfik und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt. Hauptthemen laut MEDLINE: Poly (ADP-Ribose) Polymerase-1, Poly(ADP-ribose) Polymerase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: Princess Nourah bint Abdulrahman University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A possible method for improving anti‐cancer efficacy is the combination of the inhibition of epidermal growth factor receptor (EGFR) and poly (ADP‐ribose) polymerase‐1 (PARP‐1). This work describes the rational design, synthesis, and complete characterization of a novel class of boomerang‐shaped dual PARP‐1/EGFR inhibitors ( 3a – o ). HepG‐2 and MDA‐MB‐231 cancer cell lines were used to test the synthesized compounds’ antiproliferative potential; MDA‐MB‐231 cells showed greater sensitivity. Compounds 3h , 3i , and 3j had the strongest cytotoxic effects among the series, with IC 50 values of 0.23, 0.90, and 1.40 µM, respectively, against MDA‐MB‐231 cells. Compared with the reference medications erlotinib and olaparib, compound 3h showed the highest dual inhibition (EGFR IC 50 = 1.62 µM and PARP‐1 IC 50 = 0.36 µM) in enzymatic experiments, demonstrating that these compounds effectively inhibited both EGFR and PARP‐1. Compound 3h strongly promoted apoptosis in MDA‐MB‐231 cells, increasing the total apoptotic population to 20.04% and causing G1‐phase cell‐cycle arrest, as determined by mechanistic studies. In vivo tumor growth inhibition trials showed a tumor inhibition rate (TIR%) of 41.4% for compound 3h compared to 48.8% for doxorubicin (DOX). Liver function biomarkers and hematological parameters remained within the acceptable levels following compound 3h treatment. The dual‐target activity of compound 3h was further validated by molecular docking and molecular dynamics simulations, which demonstrated persistent binding contacts within the active sites of PARP‐1 and EGFR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsHumansErbB ReceptorsDrug DesignAnimalsFemaleApoptosisMDA-MB-231 CellsCell ProliferationMolecular Docking SimulationCell Line, TumorHep G2 CellsMiceStructure-Activity RelationshipXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Boomerang‐shaped compoundsapoptosis inductiondual inhibitorsin silico studiesin vivo studies

Substanzen

ErbB ReceptorsPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsEGFR protein, humanPARP1 protein, human

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alsalam University, Tanta, Egypt.
  • Department of Chemistry, The American University in Cairo, New Cairo, Egypt.
  • Department of Chemistry, College of Science, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Department of Biochemistry, School of Life and Medical Sciences, University of Hertfordshire hosted by Global Academic Foundation, Cairo, Egypt.
  • Department of Pharmacology & Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.

ORCID-Profile: Haytham O Tawfik, Amr Tayel, Salma M Hefny, Nada K Sedky, Anwar A El-Hamaky, Nourhan A Khattab, Ahmed K B A W Farouk, Moataz A Shaldam, Wagdy M Eldehna, Mohamed S Nafie

Förderung

  • Princess Nourah bint Abdulrahman University

Zitieren

APA

Tawfik, H. O., Tayel, A., Hefny, S. M., Al-Warhi, T., Sedky, N. K., El-Hamaky, A. A., Khattab, N. A., Farouk, A. K. B. A. W., Shaldam, M. A., Eldehna, W. M., & Nafie, M. S. (2026). Molecular Boomerangs Against Cancer: Design, Synthesis, Biological Evaluation, and In Silico Study of Novel Dual PARP‐1/EGFR Inhibitors. Drug Development Research, 87(4). https://doi.org/10.1002/ddr.70325

Vancouver

Tawfik HO, Tayel A, Hefny SM, Al-Warhi T, Sedky NK, El-Hamaky AA, et al. Molecular Boomerangs Against Cancer: Design, Synthesis, Biological Evaluation, and In Silico Study of Novel Dual PARP‐1/EGFR Inhibitors. Drug Development Research. 2026;87(4). doi:10.1002/ddr.70325

BibTeX
@article{Tawfik2026,
  author = {Tawfik, Haytham O and Tayel, Amr and Hefny, Salma M and Al-Warhi, Tarfah and Sedky, Nada K and El-Hamaky, Anwar A and Khattab, Nourhan A and Farouk, Ahmed K B A W and Shaldam, Moataz A and Eldehna, Wagdy M and Nafie, Mohamed S},
  title = {Molecular Boomerangs Against Cancer: Design, Synthesis, Biological Evaluation, and In Silico Study of Novel Dual PARP‐1/EGFR Inhibitors},
  journal = {Drug Development Research},
  year = {2026},
  volume = {87},
  number = {4},
  doi = {10.1002/ddr.70325}
}
Kostenlos starten →